Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Kite nets $347.9mm through public stock sale

Executive Summary

Kite Pharma Inc. (cancer immunotherapies) netted $347.9mm through the public sale of 4.75mm common shares at $75. Proceeds will support future commercialization of axicabtagene ciloleucel in the US and Europe (currently in Phase II/III trials for diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma, and transformed follicular lymphoma), continued development of leukemia and lymphoma candidate KTEC19, and additional work on other CAR/TCR projects in the company's pipeline.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

Advertisement
UsernamePublicRestriction

Register